Sub 5 nm Gd3+–Hemoporfin Framework Nanodots for Augmented Sonodynamic Theranostics and Fast Renal Clearance,Advanced Healthcare Materials

当前位置： X-MOL 学术 › Adv. Healthcare Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sub 5 nm Gd3+–Hemoporfin Framework Nanodots for Augmented Sonodynamic Theranostics and Fast Renal Clearance
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2021-08-07 , DOI: 10.1002/adhm.202100703
Peng Geng ₁ , Nuo Yu ₁ , Xiaohan Liu ₁ , Qin Zhu ₁ , Mei Wen ₁ , Qian Ren ₁ , Pu Qiu ₁ , Haijun Zhang _{2,

3} , Maoquan Li ₃ , Zhigang Chen ₁

Affiliation

Metal–organic nanomaterials have emerged as promising therapeutic agents to produce reactive oxygen species (ROS) under ultrasound (US) or light irradiation for tumor treatments. However, their relatively large sizes (ranging from tens to hundreds of nanometers) usually lead to low ROS utilization and body metabolism, thus enlarging their long-term toxicity and low therapeutic effect. To solve these shortcomings, herein the ultrasmall Gd³⁺–hemoporfin framework nanodots (GdHF-NDs， ≈5 nm) is reported as efficient nano-sonosensitizers. Compared with GdHF aggregation (GdHF-A, ≈400 nm), the ultrasmall GdHF-NDs generate 2.3-fold toxic ROS amount under similar conditions, due to shorter diffusion path and larger relative specific surface area. When the GdHF-NDs dispersion is introvenously injected into tumor-bearing mouse, they are accumulated within tumors to provide high magnetic resonance imaging (MRI) contrast. Under US irradiation, the GdHF-NDs achieve a better sonodynamic therapeutic efficacy for tumors, compared with that from GdHF-A. More importantly, owing to ultrasmall size, most of GdHF-NDs can be rapidly cleared through the renal pathway. Therefore, GdHF-NDs can be used as a biosafety and high-performance sonodynamic agent for cancer theranostics.

中文翻译：

亚 5 nm Gd3+–Hemoporfin 框架纳米点用于增强声动力学治疗和快速肾脏清除

金属有机纳米材料已成为有前途的治疗剂，可在超声 (US) 或光照射下产生用于肿瘤治疗的活性氧 (ROS)。然而，它们相对较大的尺寸（从几十到几百纳米）通常会导致 ROS 利用率和身体代谢率低，从而扩大了它们的长期毒性和低治疗效果。为解决这些缺点，本文提出了超小 Gd ³⁺– 血卟啉骨架纳米点（GdHF-NDs，≈5 nm）据报道是有效的纳米声敏剂。与 GdHF 聚集体（GdHF-A，≈400 nm）相比，由于更短的扩散路径和更大的相对比表面积，超小型 GdHF-ND 在类似条件下产生 2.3 倍的有毒 ROS 量。当 GdHF-NDs 分散体被静脉注射到荷瘤小鼠体内时，它们会在肿瘤内积累以提供高磁共振成像 (MRI) 对比度。在美国辐射下，与 GdHF-A 相比，GdHF-NDs 对肿瘤具有更好的声动力学治疗效果。更重要的是，由于体积超小，大多数 GdHF-NDs 可以通过肾脏途径快速清除。因此，GdHF-NDs 可用作癌症治疗诊断学的生物安全和高性能声动力剂。

更新日期：2021-09-22

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11